Загрузка...
Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major...
Сохранить в:
| Опубликовано в: : | Int J Mol Sci |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5187798/ https://ncbi.nlm.nih.gov/pubmed/27916828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17121998 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|